By Stephen Nakrosis
The American depositary shares of Legend Biotech were trading lower in the after-hours market, following news the company commenced an underwritten public offering of $225 million of ADSs.
After the bell, the cell therapy company's ADSs were trading 8% lower, at $30.84. The ADSs finished the day's regular session with a gain of less than 1%, closing at $33.52.
Year to date, the company's ADSs have gained over 54%.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
June 17, 2026 17:40 ET (21:40 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.